Responsive Neurostimulation Reduces Focal Seizures by 82% at Three Years

Managing drug-resistant focal epilepsy remains a significant clinical challenge, as approximately one-third of patients continue to experience disabling seizures despite trials of multiple antiseizure medications [1, 2]. When resective surgery is not feasible, clinicians often utilize neuromodulation modalities such as vagus nerve stimulation, deep brain stimulation, and responsive neurostimulation (a closed-loop system that monitors brain activity and delivers targeted electrical pulses to interrupt detected ictal patterns) [3, 4]. While these therapies have established efficacy in randomized controlled trials, the transition to real-world clinical practice often reveals variations in long-term outcomes and safety profiles [5, 6]. Long-term monitoring is particularly critical for assessing the risk of sudden unexplained death in epilepsy (a fatal complication where a patient dies without a clear structural or toxicological cause), which remains a primary concern in this patient population [7]. A new prospective study now offers fresh insights into the longitudinal performance and safety of responsive neurostimulation in a large clinical cohort, providing practicing neurologists with clearer expectations for long-term patient management.